🔵 Today is the day!
There’s still time to join us LIVE for a critical conversation about protecting newborns from RSV.

📅 TODAY — Nov. 21
⏰ 12 PM ET / 9 AM PT
🔗 Register & Join Live: bit.ly/NMQF1121

#RSV #RSVPrevention #MaternalHealth #InfantHealth #HealthEquity #NMQF #SHC #NewbornCare

We’re just two days away from a powerful discussion on newborn health and RSV prevention.

Join us!
📅 Friday, Nov. 21
⏰ 12 PM ET / 9 AM PT
🔗 Register: bit.ly/NMQF1121

Don’t miss it! 💙🍼

#RSV #RSVPrevention #InfantHealth #MaternalHealth #HealthEquity #NMQF #SHC

🚨 Happening This Friday! 🚨

A Safe Start for Every Baby:
What Every Parent, Clinician, Hospital, and Payer Should Know About Preventing RSV in Newborns

📅 Friday, Nov. 21
⏰ 12 PM ET / 9 AM PT
🔗 Register: bit.ly/NMQF1121

#RSV #RSVPrevention #MaternalHealth #InfantHealth #NMQF #SHC #NewbornCare

WTF Wire

Prepare for the 2025-26 #respiratoryvirusseason. Learn who should get vaccinated against Covid-19, flu, and RSV, where to get shots, and the best timing. #WTFWire #FluShot #RSVVaccine #HealthAwareness #Immunization #FluSeason2025 #Covid19Prevention #RSVPrevention www.wtfwire.com/health/2025-...

RSV Prevention Criteria for the 2023–2024 Season [Medicaid] • Beyfortus (nirsevimab), a long-acting monoclonal antibody product, was approved by the US Food and Drug Administration (FDA) on July 17, 2023, for use in newborns and infants to protect against (medically attended) respiratory syncytial virus (RSV).1

AL. State Agencies:Alabama News Beacon #RSVPrevention #Beyfortus #MonoclonalAntibody #InfantHealth #FDAApproval

For the first time there are safe and effective RSV prevention treatments and they significantly reduce hospitalizations in infants Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all their hospitalizations. However,...

Baylor College of Medicine reports that the implementation of new #RSV prevention strategies, including maternal vaccination and infant antibody treatments, has led to a significant reduction in hospitalizations among infants aged 0–7 months.

#AccessPress #BaylorCollegeOfMedicine #RSVPrevention

WHO adds first maternal RSV vaccine to prequalification list - PharmaTimes Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants

#Abrysvo #Pfizer #WHO #WorldHealthOrganization #maternalRSVvaccine #RSVprevention #respiratorysyncytialvirus #RSV #RSVvaccine #prequalifiedvaccines #RSVinfection #maternalvaccination #GAVI #Unicef #publichealth #passiveimmunisation
pharmatimes.com/news/who-add...

This season, protect yourself and your loved ones from Respiratory Syncytial Virus! RSV can cause serious respiratory illness, especially in young children, older adults, and those with weakened immune systems.

#ACLAMO #RSVPrevention #Vaccination #StayHealthy #ProtectYourFamily #RSVAwareness

New Vaccine Prevents Severe RSV Illness A recent study showed the new vaccine was more than 90% effective in the prevention of hospitalizations and emergency department visits due to RSV among those 60 years old or older.

A recent study reveals that the new RSV vaccine is 91% effective in preventing hospitalizations and emergency department visits among adults 60+ at increased risk. This large-scale analysis underscores its potential in reducing severe RSV-related illness. #RSVPrevention #MedicalResearch